Invion (AU:IVX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Invion Limited has issued 588,236 new shares at $0.17 each, as it continues discussions with RMW Cho Group to potentially expand its Photosoft™ technology rights. This technology is part of Invion’s innovative approach to cancer treatment, using photodynamic therapy as a non-invasive alternative to traditional methods. The company remains a key player in the life sciences sector, with its shares actively traded on the ASX.
For further insights into AU:IVX stock, check out TipRanks’ Stock Analysis page.
